Table 1

Characteristics of included studies

Study	Study design	Origin	Definition	Symptom onset, hour	Sample size	Antiplatelet therapy	IVT therapy	Outcome
Chen 2023	RCT	China	NIHSS≤5	＜4.5 hour	719	DAPT	Alteplase	①②③④
Duan 2023	Cohort study	China	NIHSS≤5	＜4.5 hour	1177	DAPT/aspirin alone	Intravenous thrombolysis	①②③
Sykora 2023	Cohort study	Austria	NIHSS≤3	NA	718	DAPT	Intravenous thrombolysis	①④
Wang 2021	Cohort study	China	NIHSS≤3	＜4.5 hour	830	DAPT/aspirin alone	Intravenous thrombolysis	①②
Lan 2020	Cohort study	China	NIHSS≤5	NA	218	DAPT	Alteplase	①②③④
Khatri 2018	RCT	United States	NIHSS≤5	＜3 hour	313	Aspirin alone	Alteplase	①②③④

①Long-term functional outcomes; ②death; ③stroke or other vascular events; ④symptomatic intracranial haemorrhage.
DAPT, dual antiplatelet therapy; IVT, intravenous thrombolysis; NA, not applicable; NIHSS, National Institutes of Health Stroke Scale; RCT, randomised clinical trial.